10.04.2019
Annual Report 2018 preliminary unaudited
Regenics post a positive 2018 result with topline in excess of 1.68 mill NOK. 
13.03.2019
Patent annuities paid 2019
Regenics patents due for annuity/fee payments in May 2019 have been paid and continued by our patent legal consultant.
06.03.2019
Filing of additional Hong Kong patent application
The Patents registry of the Hong Kong Intellectual Property Department has verified receipt of Hong Kong Patent Application No. 16104205.5 from Regenics on January 25th 2019. The Hong Kong patent...
06.03.2019
Filing of new US provisional patent application
Filing of new US provisional patent application
28.02.2019
Board Meeting No 2 2019
March 5th 2019. 
23.01.2019
Regenics Board Meeting No 1 2019
January 23rd 2019.  
23.01.2019
Protocol Extraordinary Annual Meeting January 23rd 2019
January 23rd 2019 Protocoll of Extraordinary Annual Meeting January 23rd 2019. The Extraordinary Annual Meeting 2019 took place in the Companys office, Karvesvingen. 2, Oslo
18.12.2018
New EPO Patent granted 2018
New EPO patent
10.12.2018
Eqology AS launch Collagen Booster Serum
 An important commercial milestone has been reached for Regenics December 10th with the launch of the ground breaking EQ Collagen Boosting Serum from the Norwegian Direct Selling Company Eqology AS.  
30.11.2018
Protocol from Extraordinary Annual Meeting September 26th 2018
September 26th 2018 Protocol of Extraordinary Annual Meeting September 26th 2018. The Annual Meeting 2017 took place in the Companys office, Karvesvingen. 2, Oslo
29.11.2018
Notification of grant:Divisional EPO patent
Notification of grant: Divisional EPO patent
27.11.2018
Adam Robertson new Chief Scientific Officer in Regenics
 Adam Robertson has today signed up as  Business Developer for Regenics AS.  Adam is part of the team that develops cutting  edge skin care and wound healing at Regenics.  Adam is...
07.11.2018
Regenics Board Meeting No 4 2018
November 7th 2018
17.09.2018
Bernat Rocarols - New Business Developer Regenics
   
09.09.2018
Regenics Board Meeting No 3 2018
September 9th 2018
19.08.2018
EPO National validation 2018
EPO Patent validation 
30.06.2018
Regenics Board Meeting No 2 2018
June 13th 2018
28.06.2018
Protocol Annual Meeting 2018
June 28th 2018 Protocoll of Regenics Annual Meeting on June 28th 2018. The Annual Meeting 2018 took place in the Companys office, Karvesvingen. 2, Oslo
19.06.2018
US patent granted June 2018
 
15.06.2018
Upcoming event: 37C Health Meeting Stavanger
Regenics AS attends the 37C "Digitalization in Health" meeting on June 19-20 of June 2018 at Forus Stavanger. CEO Henrik Lund, co-chairs the meeting    
13.06.2018
Regenics AS Annual Report 2017
Regenics post a small positive 2017 result with topline in excess of 0.047 mill NOK. 
13.06.2018
Notice of Annual Meeting June 28th 2018
June 13th 2018 Notice of Annual Meeting June 28th 2018. The Annual Meeting 2018 will take place at the Companys site Karvesvingen 2. 2, Oslo from 2 pm to 5 pm.
23.05.2018
Innovation Norway grants Innovation Contract to Regenics AS
Regenics AS was May 18th 2018 awarded an Innovation Contract from Innovation Norway. The Innovation Contract has a total budget of 14.3 million NOK to support the development of Vernex®...
07.05.2018
Updated share info May 7th 2018
Regenics AS provides updated share info and shareowner distribution as per May 7th 2018

Page 1 of 5   >  >>

Regenics AS has developed a number of assays and techniques to study effects of various substances on skin cells both in vitroin vivo and in the clinic. Our focus is to develop products and techniques for therapeutic skin applications and to improve skin appearance.